Caplacizumab (Cablivi) for iTTP
Date: October 19, 2020
Issue #:
1609Summary:
Caplacizumab-yhdp (Cablivi– Sanofi /Genzyme), a
von Willebrand factor-directed antibody fragment, has
been approved by the FDA for use in combination with
plasma exchange and immunosuppressive therapy
for treatment of immune-mediated thrombotic
thrombocytopenic purpura (iTTP; formerly called
acquired thrombotic thrombocyto penic purpura
[aTTP]) in adults. It is the first drug to be approved in
the US for this indication.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Source Type: research
More News: Drugs & Pharmacology | von Willebrand Disease